Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan E Cohen

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Human Brain Mapping|February 15, 2012
Emotional brain rhythms and their impairment in post-traumatic patientsJonathan E Cohen, Hadar Shalev, Roee Admon, et al.
Human Molecular Genetics|March 29, 2013
Defective skeletal muscle growth in lamin A/C-deficient mice is rescued by loss of Lap2αTatiana V Cohen, Viola F Gnocchi, Jonathan E Cohen, et al.
Immunologic Research|July 22, 2022
The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphomaRony Shreberk-Hassidim, Anat Geiger-Maor, Galit Eisenberg, et al.
Frontiers in Immunology|May 29, 2026
Prediction of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD-1 inhibition directly from histopathology slides using inferred transcriptomicsBohdana Chayen, Gal Dinstag, Omer Tirosh, et al.
JAAD International|November 17, 2025
Impact of COVID-19 on cutaneous squamous cell carcinoma severity in a tertiary referral center in Israel: Lessons for future pandemicsDeborah Korn, Sivan Sheffer-Levi, Maayan Eitan-Wexler, et al.
Radiation Research|April 14, 2024
Gastrointestinal Acute Radiation Syndrome: Mechanisms, Models, Markers, and Medical CountermeasuresThomas A Winters, Libero Marzella, Olivia Molinar-Inglis, et al.
Elife|March 4, 2020
SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpointEmma Hajaj, Galit Eisenberg, Shiri Klein, et al.
Investigational New Drugs|April 14, 2021
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumorsGerald S Falchook, Marc Peeters, Sylvie Rottey, et al.
Nature Biotechnology|September 8, 2022
Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnosticsVadim Fedyuk, Nir Erez, Noa Furth, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 24, 2025
Proceedings: PET Drugs-A 2023 Workshop on Product Quality, Regulatory Submissions, Facility Inspections, and Benefit-Risk ConsiderationsSue Bunning, Danae Christodoulou, Jonathan E Cohen, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Human Brain Mapping|February 15, 2012
Emotional brain rhythms and their impairment in post-traumatic patientsJonathan E Cohen, Hadar Shalev, Roee Admon, et al.
Human Molecular Genetics|March 29, 2013
Defective skeletal muscle growth in lamin A/C-deficient mice is rescued by loss of Lap2αTatiana V Cohen, Viola F Gnocchi, Jonathan E Cohen, et al.
Immunologic Research|July 22, 2022
The role of immune checkpoint receptors in the malignant phenotype of cutaneous T cell lymphomaRony Shreberk-Hassidim, Anat Geiger-Maor, Galit Eisenberg, et al.
Frontiers in Immunology|May 29, 2026
Prediction of clinical outcomes of advanced cutaneous squamous cell carcinoma to PD-1 inhibition directly from histopathology slides using inferred transcriptomicsBohdana Chayen, Gal Dinstag, Omer Tirosh, et al.
JAAD International|November 17, 2025
Impact of COVID-19 on cutaneous squamous cell carcinoma severity in a tertiary referral center in Israel: Lessons for future pandemicsDeborah Korn, Sivan Sheffer-Levi, Maayan Eitan-Wexler, et al.
Radiation Research|April 14, 2024
Gastrointestinal Acute Radiation Syndrome: Mechanisms, Models, Markers, and Medical CountermeasuresThomas A Winters, Libero Marzella, Olivia Molinar-Inglis, et al.
Elife|March 4, 2020
SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpointEmma Hajaj, Galit Eisenberg, Shiri Klein, et al.
Investigational New Drugs|April 14, 2021
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumorsGerald S Falchook, Marc Peeters, Sylvie Rottey, et al.
Nature Biotechnology|September 8, 2022
Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnosticsVadim Fedyuk, Nir Erez, Noa Furth, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 24, 2025
Proceedings: PET Drugs-A 2023 Workshop on Product Quality, Regulatory Submissions, Facility Inspections, and Benefit-Risk ConsiderationsSue Bunning, Danae Christodoulou, Jonathan E Cohen, et al.
Pageof 5